WO2006072792A3 - Composes se liant au site actif des proteines kinases - Google Patents

Composes se liant au site actif des proteines kinases Download PDF

Info

Publication number
WO2006072792A3
WO2006072792A3 PCT/GB2006/000034 GB2006000034W WO2006072792A3 WO 2006072792 A3 WO2006072792 A3 WO 2006072792A3 GB 2006000034 W GB2006000034 W GB 2006000034W WO 2006072792 A3 WO2006072792 A3 WO 2006072792A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
treatment
nerve cell
trauma
bind
Prior art date
Application number
PCT/GB2006/000034
Other languages
English (en)
Other versions
WO2006072792A2 (fr
Inventor
Veronique Birault
Clifford John Harris
Roger Crossley
Original Assignee
Galapagos Nv
Veronique Birault
Clifford John Harris
Roger Crossley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv, Veronique Birault, Clifford John Harris, Roger Crossley filed Critical Galapagos Nv
Publication of WO2006072792A2 publication Critical patent/WO2006072792A2/fr
Publication of WO2006072792A3 publication Critical patent/WO2006072792A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

L'invention concerne un ou plusieurs composés qui sont des inhibiteurs d'une sérine/thréonine kinase et, d'une manière plus spécifique, de la Rho kinase (ROK, ROCK). Ces composés peuvent être utilisé dans la fabrication d'un médicament pour le traitement ou la prévention d'une maladie choisie dans le groupe constitué : d'une affection oculaire telle que la dégénérescence maculaire liée à l'âge, une maladie de la glande lacrymale ou la rétinopathie diabétique ou la suppression du développement de neurites et donc à une affection nécessitant l'extension et la connectivité de cellules nerveuses, la régénération des neurones, l'induction du développement de nouveaux axones et la promotion du (re)câblage d'axones, la réparation de lésions des neurones dans le SNC provoquées par un traumatisme (par exemple un accident cérébrovasculaire, une lésion cérébrale traumatique, etc.) ou par une neurodégénérescence (par exemple la maladie d'Alzheimer, la maladie de Parkinson, etc.), à la réparation ou la récupération de troubles tels qu'une lésion de la moelle épinière et le traitement de ceux-ci et la réduction des effets subséquents de ceux-ci ou de la douleur provoquée par une lésion des cellules nerveuses telle que celle consécutive à un traumatisme ou à une amputation par exemple dans le traitement de la douleur neuropathique. Les composés selon l'invention sont choisis dans un groupe spécifique de composés qui comprend des composés représentés par la formule (I) ou (II), dans laquelle R1, R2, R3, R4, R5 et R6 sont tels que définis dans le descriptif.
PCT/GB2006/000034 2005-01-07 2006-01-06 Composes se liant au site actif des proteines kinases WO2006072792A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0500226.6A GB0500226D0 (en) 2005-01-07 2005-01-07 Compounds which bind to the active site of protein kinase enzymes
GB0500226.6 2005-01-07

Publications (2)

Publication Number Publication Date
WO2006072792A2 WO2006072792A2 (fr) 2006-07-13
WO2006072792A3 true WO2006072792A3 (fr) 2007-01-11

Family

ID=34203716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/000034 WO2006072792A2 (fr) 2005-01-07 2006-01-06 Composes se liant au site actif des proteines kinases

Country Status (2)

Country Link
GB (1) GB0500226D0 (fr)
WO (1) WO2006072792A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
JPWO2009107391A1 (ja) * 2008-02-27 2011-06-30 武田薬品工業株式会社 ６員芳香環含有化合物
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
CN105985322A (zh) * 2015-03-03 2016-10-05 苏州翔实医药发展有限公司 氨基吡嗪化合物及其用途
WO2017064119A1 (fr) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement de la non-perfusion des capillaires de la rétine
EP4088719A1 (fr) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Procédés et compositions pharmaceutiques pour le traitement de non-perfusion capillaire rétinienne

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087853A1 (fr) * 2000-05-17 2001-11-22 Universite Catholique De Louvain Derives de pyrazine et d'imidazopyrazine comme antioxydants
WO2002024681A2 (fr) * 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Derives de pyrazine tenant lieu de modulateurs de tyrosine kinase
US20030103957A1 (en) * 2001-04-12 2003-06-05 Mckerracher Lisa Fusion proteins
WO2003062227A1 (fr) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Inhibiteurs de kinase rho
WO2004085409A2 (fr) * 2003-03-28 2004-10-07 Biofocus Discovery Ltd Bibliotheque de composes
WO2005003101A2 (fr) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Composes se liant au site actif d'enzymes proteine kinases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087853A1 (fr) * 2000-05-17 2001-11-22 Universite Catholique De Louvain Derives de pyrazine et d'imidazopyrazine comme antioxydants
WO2002024681A2 (fr) * 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Derives de pyrazine tenant lieu de modulateurs de tyrosine kinase
US20030103957A1 (en) * 2001-04-12 2003-06-05 Mckerracher Lisa Fusion proteins
WO2003062227A1 (fr) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Inhibiteurs de kinase rho
WO2004085409A2 (fr) * 2003-03-28 2004-10-07 Biofocus Discovery Ltd Bibliotheque de composes
WO2005003101A2 (fr) * 2003-07-02 2005-01-13 Biofocus Discovery Limited Composes se liant au site actif d'enzymes proteine kinases

Also Published As

Publication number Publication date
WO2006072792A2 (fr) 2006-07-13
GB0500226D0 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
WO2021178237A3 (fr) Compositions oligonucléotidiques et méthodes associées
WO2006072792A3 (fr) Composes se liant au site actif des proteines kinases
WO2006071548A3 (fr) Analogues d'aminopyrazine servant a traiter le glaucome et d'autres maladies ou etats medies par rho kinase
WO2009127642A3 (fr) Utilisation d’inhibiteurs de lrrk2 pour maladies neurodégénératives
WO2007022470A3 (fr) Methodes et compositions pour le traitement de maladies neurologiques
PH12015501207A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
WO2010048332A3 (fr) Composés de traitement de maladies et troubles ophtalmiques
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
UA88634C2 (en) Quaternized quinuclidine esters
WO2007076360A8 (fr) (indazol-5-yl)-pyrazines et (1,3-dihydro-indol-2-un)- pyrazines pour le traitement de maladies et de conditions a mediation de rho kinase
UA83899C2 (uk) Сполуки імідазолу для лікування нейродегенеративних розладів
WO2006091546A3 (fr) Utilisation du fluide amniotique en traitement d'affections et de lesions oculaires
WO2008112651A3 (fr) Aminopyrimidines utiles en tant qu'inhibiteurs des protéines kinases
WO2006050045A3 (fr) Utilisation d'inhibiteurs de jun n-terminal kinases pour le traitement de la retinophatie glaucomateuse et de maladies oculaires
TW200602297A (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
WO2010028088A3 (fr) Composants à liaison soufre pour le traitement de maladies et de troubles ophtalmiques
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.
WO2007035722A8 (fr) Methodes et compositions permettant de stimuler la neurogenese et d'inhiber la degenerescence neuronale
WO2005097114A3 (fr) Composes de thiazole sulfamide utiles pour le traitement des maladies neurodegeneratives
WO2005095348A3 (fr) Composes pyrazole-amines utilises dans le traitement des troubles neurodegeneratifs
WO2007034326A3 (fr) Composes imidazoles pour le traitement de troubles neurologiques
WO2004028468A3 (fr) Procedes et compositions pour le traitement des troubles neurologiques
WO2009005838A3 (fr) Procédé de préparation d'une solution basique non corrosive et ses procédés d'utilisation
TW201129376A (en) A screening method of a medicament effective for treating dry eye and/or corneal/conjunctival disorders and a pharmaceutical composition obtained from the method
WO2005016267A3 (fr) Composes d'oxazole destines au traitement de troubles neurodegenerescents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06701082

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6701082

Country of ref document: EP